ARTICLE SUMMARY:
Bigfoot Biomedical’s recent deal to integrate Abbott’s FreeStyle Libre glucose sensor technology into its automated insulin delivery system is a major step toward Bigfoot’s goal of creating the most patient-friendly AP system possible. In this Q&A, Bigfoot CEO Jeffrey Brewer lays out the rationale for the deal and how it fits into the company’s long-term, patient-centric vision.
Collaboration is the name of the game in the diabetes device field these days, and the past few months have certainly followed that trend, with a number of new deals announced recently (see Figure 1).
